- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Dr Vibeke Strand: The Current State of Immunology Biosimilars and the Promise of Future Savings
In light of 2 blockbuster originators, namely Humira (adalimumab) and Stelara (ustekinumab), losing market exclusivity in 2023, 3 doctors penned supplement in The American Journal of Managed Care®. On this episode, Vibeke Strand, MD, one of the co-authors, explored how health systems can take charge and boost biosimilar adoption.
It's no secret that the immunology space for biosimilars is growing and growing fast, with between 8 and 10 adalimumab biosimilars and at least 2 ustekinumab biosimilars expected to launch in the United States throughout 2023. In light of 2 of the most profitable originators, namely Humira (adalimumab) and Stelara (ustekinumab), losing market exclusivity around the same time, 3 doctors in the immunology space penned a 3-article supplement in The American Journal of Managed Care® entitled "Biosimilars for Immune-Mediated Inflammatory Diseases: 2022 Update."
The Center for Biosimilars®, the sister website of The American Journal of Managed Care®, is conducting a multimedia interview series with the authors to expand on some of the information presented in the supplement. On this episode of Not So Different, we spoke with Vibeke Strand, MD, one of the co-authors and an adjunct clinical professor in the Division of Immunology/Rheumatology at Stanford University School of Medicine. We discussed the article "Overview of Biosimilars for Immune-Mediated Inflammatory Diseases: Summary of Current Evidence" as well as how health systems can take charge and try to boost biosimilar adoption.
Show notes
To read all the articles within the supplement, click here.
To read the article references in this episode, click here.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
